Amgen – Oppenheimer Stick to Their Buy Rating for Amgen Inc By Fintech Zoom
Oppenheimer analyst Jay Olson maintained a Buy rating on Amgen Inc (NASDAQ:) on Monday, setting a price target of $266, which is approximately 5.20% above the present share price of $252.86.
Olson expects Amgen Inc to post earnings per share (EPS) of $2.78 for the first quarter of 2021.
The current consensus among 16 TipRanks analysts is for a Moderate Buy rating of shares in Amgen, with an average price target of $261.29.
The analysts price targets range from a high of $295 to a low of $200.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $6.63 billion and a net profit of $2.01 billion. The company’s market cap is $146.04 billion.
According to TipRanks.com, Oppenheimer analyst Jay Olson is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 1.8% and a 45.60% success rate.
Founded in 1980, California-based Amgen, Inc. is one of the world’s leading biotechnology companies, which is engaged in the discovery, development, manufacture and marketing of human therapeutics. It primarily focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas.
Fintech Zoom or anyone involved with Fintech Zoom will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.